These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32661081)

  • 1. Botulinum neurotoxin (BoNT) treatment in functional movement disorders: long-term follow-up.
    Dreissen YE; Lambert F; Dijk JM; Koelman JH; Tijssen MA
    J Neurol Neurosurg Psychiatry; 2020 Oct; 91(10):1120-1121. PubMed ID: 32661081
    [No Abstract]   [Full Text] [Related]  

  • 2. An update on new and unique uses of botulinum toxin in movement disorders.
    Jankovic J
    Toxicon; 2018 Jun; 147():84-88. PubMed ID: 28888928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin for the treatment of bruxism.
    Tinastepe N; Küçük BB; Oral K
    Cranio; 2015 Oct; 33(4):291-8. PubMed ID: 26715152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin in the treatment of neurological disorders.
    Denislic M; Pirtosek Z; Vodusek DB; Zidar J; Meh D
    Ann N Y Acad Sci; 1994 Mar; 710():76-87. PubMed ID: 8154763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia.
    Spiegel LL; Ostrem JL; Bledsoe IO
    Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32429600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-Related Quality of Life Outcomes from Botulinum Toxin Treatment in Spasticity.
    Roncoroni LP; Weiss D; Hieber L; Sturm J; Börtlein A; Mayr I; Appy M; Kühnler B; Buchthal J; Dippon C; Arnold G; Wächter T
    Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32375388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum Toxin in Movement Disorders: An Update.
    Anandan C; Jankovic J
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33430071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Effectiveness of Treatment with Botulinum Toxin on Sleep Quality in Stroke-Related Spasticity.
    Deveci H
    J Stroke Cerebrovasc Dis; 2020 Oct; 29(10):105160. PubMed ID: 32912522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review.
    Mitchell SD; Sidiropoulos C
    Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33808714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin.
    Truzzi JC
    Rev Recent Clin Trials; 2015; 10(2):128-34. PubMed ID: 25880125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin: a novel therapy for clozapine-induced sialorrhoea.
    Verma R; Anand KS
    Psychopharmacology (Berl); 2018 Jan; 235(1):369-371. PubMed ID: 29196826
    [No Abstract]   [Full Text] [Related]  

  • 13. The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems.
    Kumar R; Dhaliwal HP; Kukreja RV; Singh BR
    Semin Neurol; 2016 Feb; 36(1):10-9. PubMed ID: 26866491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The auditory startle response in relation to outcome in functional movement disorders.
    Dreissen YEM; Koelman JHTM; Tijssen MAJ
    Parkinsonism Relat Disord; 2021 Aug; 89():113-117. PubMed ID: 34274620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin in movement disorders.
    Papapetropoulos S; Singer C
    Semin Neurol; 2007 Apr; 27(2):183-94. PubMed ID: 17390263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin: State of the art.
    Jankovic J
    Mov Disord; 2017 Aug; 32(8):1131-1138. PubMed ID: 28639368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal.
    Jost WH
    Toxins (Basel); 2021 Jan; 13(2):. PubMed ID: 33503872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical management of botulinum toxin therapy. Introduction.
    Lim EC; Bhidayasiri R; Rosales RL; Kaji R
    Parkinsonism Relat Disord; 2011 Nov; 17 Suppl 1():S1-2. PubMed ID: 21999888
    [No Abstract]   [Full Text] [Related]  

  • 19. Physician Preferences for Botulinum Toxin Injections in Anticoagulated Patients with Spasticity.
    Kassam A; Phadke CP; Ismail F; Boulias C
    Can J Neurol Sci; 2016 Jul; 43(4):581-3. PubMed ID: 26940640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin B treatment in children with spastic movement disorders: a pilot study.
    Schwerin A; Berweck S; Fietzek UM; Heinen F
    Pediatr Neurol; 2004 Aug; 31(2):109-13. PubMed ID: 15301829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.